Potential Role of microRNA 410 and BIRC7 Pathways in Recurrent Spontaneous Miscarriage

Launched by NESMA GAMAL · Dec 12, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the potential role of certain biological pathways, specifically microRNA 410 and BIRC7, in understanding recurrent spontaneous miscarriages. Recurrent spontaneous miscarriage (RSA) is defined as having two or three miscarriages in a row or not too far apart, and it affects about 1% to 5% of women of childbearing age. The exact causes of these miscarriages can be complex and vary from person to person, and for many women, the reasons remain unexplained.

To participate in this trial, women aged 20 to 30 who have experienced two or three consecutive or closely timed miscarriages with the same partner may be eligible. The study aims to gather more information about these miscarriages to help improve outcomes for future pregnancies. If you join the trial, you can expect to undergo some tests and assessments to better understand your situation. It's important to know that women with only one miscarriage, known causes for their miscarriages, cancer, chronic illnesses, or those over 30 will not be eligible to participate.

Gender

FEMALE

Eligibility criteria

• • Inclusion Criteria: maternal age is between 20 to 30 years and Gestational age before abortion less than 24 weeks.
• • Female with unexplained two or three consecutive or discontinuous miscarriages with the same sexual partner
• Exclusion Criteria:
• • 1. Female with one miscarriage
• • 2. Female with explained causes of miscarriage
• • 3. Female with cancer
• • 4. Female with chronic illness.
• • 5. Pregnant women above 30